SIDEBAR: FDA Drug Approvals, 2013

Get Permission

  • Ibrutinib (Imbruvica) for mantle cell lymphoma
  • Obinutuzumab (Gazyva) for chronic lymphocytic leukemia
  • Pertuzumab (Perjeta) for breast cancer
  • Paclitaxel protein-bound particles (Abraxane) for pancreatic adenocarcinoma
  • Afatinib (Gilotrif) for non-small cell lung cancer, with Therascreen EGFR RGQ PCR Kit (Qiagen) test
  • Denosumab (Xgeva) for giant cell tumor of bone
  • Lenalidomide (Revlimid) for mantle cell lymphoma
  • Trametinib (Mekinist) for melanoma
  • Dabrafenib (Tafinlar) for melanoma
  • Radium RA 223 dichloride (Xofigo injection) for prostate cancer bone metastases
  • Erlotinib (Tarceva) for non-small cell lung cancer, with Cobas EGFR Mutation Test 
  • Ado-trastuzumab emtansine (Kadcyla) for breast cancer
  • Pomalidomicde (Pomalyst) for multiple myeloma
  • Doxorubicin hydrochloride liposome injection (generic Doxil Injection) for ovarian cancer
  • Bevacizumab (Avastin) for colorectal cancer

Related Articles

FDA Approves Ibrutinib for Mantle Cell Lymphoma

The U.S. Food and Drug Administration has approved ibrutinib (Imbruvica) to treat patients with mantle cell lymphoma, a rare and aggressive form of non-Hodgkin lymphoma representing about 6% of all non-Hodgkin lymphoma cases in the United States. By the time mantle cell lymphoma is diagnosed, it...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.